

must notify the ODP of this decision. Fourth, a facility which houses many different clinics, only one or several of which are eligible, must obtain a separate Medicaid provider number for the eligible clinics. For those States which cannot generate additional Medicaid provider numbers for entities, the covered entity must discuss and implement an alternative arrangement with the States to prevent the duplicate PHS discount/Medicaid rebate potential. See 59 FR 25112 (May 13, 1994). Please note that only covered entities wishing to access the PHS discount pricing should certify their pharmaceutical Medicaid billing status to ODP.

### III. Definition of Eligible Entity "Patient"

Section 340B(a)(5)(B) of the PHS Act states that the covered entity must provide drugs, discounted under the statute, only to its patients and not resell or otherwise transfer such drugs to individuals who are not patients of the entity. To address the potential for drug resale or transfer, PHS published final entity guidelines concerning drug diversion. See 59 Fed. Reg. 25112, May 13, 1994. In part, covered entities are required to "develop and institute adequate safeguards to prevent the transfer of discounted outpatient drugs to individuals who are not eligible for the discount." To accomplish this end, entities are encouraged to utilize a separate purchasing account and separate dispensing records. To further address the potential for drug diversion, PHS is now proposing a definition of a covered entity "patient."

An individual is a "patient" of a covered entity (with the exception of State-operated AIDS drug purchasing assistance programs) only if:

1. the covered entity has established a relationship with the individual, such that the covered entity maintains records of the individual's health care; and

2. the individual receives health care services from a health care professional who is either employed by the covered entity or provides health care under contractual or other arrangements (e.g. referral for consultation) such that responsibility for the care provided remains with the covered entity; and

3. the individual receives a health care service or range of services from the covered entity which is consistent with the service or range of services for which grant funding or Federally-qualified health center look-alike status has been provided to the entity. Disproportionate share hospitals are exempt from this requirement.

An individual will not be considered a "patient" of the entity for purposes of 340B if the only health care service received by the individual from the covered entity is the dispensing of a drug or drugs for subsequent self-administration or administration in the home setting.

An individual registered in a State-operated AIDS drug purchasing assistance program receiving financial assistance under title XXVI of the PHS Act will be considered a "patient" of the covered entity for purposes of this definition if so registered as eligible by the State program.

Dated: June 5, 1995.

**Ciro V. Sumaya,**

*Administrator, Health Resources and Services Administration.*

[FR Doc. 95-19061 Filed 8-2-95; 8:45 am]

BILLING CODE 4160-15-P

### Substance Abuse and Mental Health Services Administration

#### Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies and Laboratories That Have Withdrawn From the Program

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS (Formerly: National Institute on Drug Abuse, ADAMHA, HHS).

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be identified as such at the end of the current list of certified laboratories, and will be omitted from the monthly listing thereafter.

**FOR FURTHER INFORMATION CONTACT:** Mrs. Giselle Hersh, Division of Workplace Programs, Room 13A-54, 5600 Fishers Lane, Rockville, Maryland 20857; Tel.: (301) 443-6014.

#### SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100-71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are *not* to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

Aegis Analytical Laboratories, Inc., 624 Grassmere Park Rd., Suite 21, Nashville, TN 37211, 615-331-5300  
 Alabama Reference Laboratories, Inc., 543 South Hull St., Montgomery, AL 36103, 800-541-4931/205-263-5745  
 American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 22021, 703-802-6900  
 Associated Pathologists Laboratories, Inc., 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119-5412, 702-733-7866  
 Associated Regional and University Pathologists, Inc. (ARUP), 500 Chipeta Way, Salt Lake City, UT 84108, 801-583-2787  
 Baptist Medical Center—Toxicology Laboratory, 9601 I-630, Exit 7, Little Rock, AR 72205-7299, 501-227-2783 (formerly: Forensic Toxicology Laboratory Baptist Medical Center)  
 Bayshore Clinical Laboratory, 4555 W. Schroeder Dr., Brown Deer, WI 53223, 414-355-4444/800-877-7016  
 Cedars Medical Center, Department of Pathology, 1400 Northwest 12th Ave., Miami, FL 33136, 305-325-5810  
 Centinela Hospital Airport Toxicology Laboratory, 9601 S. Sepulveda Blvd., Los Angeles, CA 90045, 310-215-6020  
 Clinical Reference Lab., 11850 West 85th St., Lenexa, KS 66214, 800-445-6917  
 CompuChem Laboratories, Inc., 3308 Chapel Hill/Nelson Hwy., Research Triangle Park, NC 27709, 919-549-8263/800-833-3984. (Formerly: CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory, Roche CompuChem Laboratories, Inc., A Member of the Roche Group)

- CompuChem Laboratories, Inc., Special Division, 3308 Chapel Hill/Nelson Hwy., Research Triangle Park, NC 27709, 919-549-8263. (Formerly: Roche CompuChem Laboratories, Inc., Special Division, A Member of the Roche Group, CompuChem Laboratories, Inc.—Special Division)
- CORNING Clinical Laboratories, South Central Division, 2320 Schuetz Rd., St. Louis, MO 63146, 800-288-7293 (formerly: Metropolitan Reference Laboratories, Inc.)
- CORNING Clinical Laboratories, 8300 Esters Blvd., Suite 900, Irving, TX 75063, 800-526-0947 (formerly: Damon Clinical Laboratories, Damon/MetPath)
- CORNING Clinical Laboratories Inc., 1355 Mittel Blvd., Wood Dale, IL 60191, 708-595-3888 (formerly: MetPath, Inc., CORNING MetPath Clinical Laboratories)
- CORNING MetPath Clinical Laboratories, One Malcolm Ave., Teterboro, NJ 07608, 201-393-5000 (formerly: MetPath, Inc.)
- CORNING National Center for Forensic Science, 1901 Sulphur Spring Rd., Baltimore, MD 21227, 410-536-1485 (formerly: Maryland Medical Laboratory, Inc., National Center for Forensic Science)
- CORNING Nichols Institute, 7470-A Mission Valley Rd., San Diego, CA 92108-4406, 800-446-4728/619-686-3200 (formerly: Nichols Institute, Nichols Institute Substance Abuse Testing (NISAT))
- Cox Medical Centers, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, 800-876-3652/417-836-3093
- Dept. of the Navy, Navy Drug Screening Laboratory, Great Lakes, IL, Building 38-H, Great Lakes, IL 60088-5223, 708-688-2045/708-688-4171
- Diagnostic Services Inc., dba DSI, 4048 Evans Ave., Suite 301, Fort Myers, FL 33901, 813-936-5446/800-735-5416
- Doctors Laboratory, Inc., P.O. Box 2658, 2906 Julia Dr., Valdosta, GA 31604, 912-244-4468
- Drug Labs of Texas, 15201 I-10 East, Suite 125, Channelview, TX 77530, 713-457-3784
- DrugProof, Division of Dynacare/Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 800-898-0180 / 206-386-2672 (formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.)
- DrugScan, Inc., P.O. Box 2969, 1119 Mearns Rd., Warminster, PA 18974, 215-674-9310
- ElSohly Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS 38655, 601-236-2609
- General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 608-267-6267
- Harrison Laboratories, Inc., 9930 W. Highway 80, Midland, TX 79706, 800-725-3784/915-563-3300 (formerly: Harrison & Associates Forensic Laboratories)
- HealthCare/MetPath, 24451 Telegraph Rd., Southfield, MI 48034, 800-444-0106 ext. 650 (formerly: HealthCare/Preferred Laboratories)
- Holmes Regional Medical Center Toxicology Laboratory, 5200 Babcock St., N.E., Suite 107, Palm Bay, FL 32905, 407-726-9920
- Jewish Hospital of Cincinnati, Inc., 3200 Burnet Ave., Cincinnati, OH 45229, 513-569-2051
- LabOne, Inc., 8915 Lenexa Dr., Overland Park, Kansas 66214, 913-888-3927 (formerly: Center for Laboratory Services, a Division of LabOne, Inc.)
- Laboratory Corporation of America, 13900 Park Center Rd., Herndon, VA 22071, 703-742-3100 (Formerly: National Health Laboratories Incorporated)
- Laboratory Corporation of America, d.b.a. LabCorp Reference Laboratory, Substance Abuse Division, 1400 Donelson Pike, Suite A-15, Nashville, TN 37217, 615-360-3992/800-800-4522 (Formerly: National Health Laboratories Incorporated, d.b.a. National Reference Laboratory, Substance Abuse Division)
- Laboratory Corporation of America, 21903 68th Ave. South, Kent, WA 98032, 206-395-4000 (Formerly: Regional Toxicology Services)
- Laboratory Corporation of America, 2540 Empire Dr., Winston-Salem, NC 27103-6710, Outside NC: 919-760-4620/800-334-8627 / Inside NC: 800-642-0894 (Formerly: National Health Laboratories Incorporated)
- Laboratory Corporation of America Holdings, 1120 Stateline Rd., Southaven, MS 38671, 601-342-1286 (Formerly: Roche Biomedical Laboratories, Inc.)
- Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 800-437-4986 (Formerly: Roche Biomedical Laboratories, Inc.)
- Laboratory Specialists, Inc., 113 Jarrell Dr., Belle Chasse, LA 70037, 504-392-7961
- Marshfield Laboratories, 1000 North Oak Ave., Marshfield, WI 54449, 715-389-3734/800-222-5835
- MedExpress/National Laboratory Center, 4022 Willow Lake Blvd., Memphis, TN 38175, 901-795-1515
- Medical College Hospitals Toxicology Laboratory, Department of Pathology, 3000 Arlington Ave., Toledo, OH 43699-0008, 419-381-5213
- Medlab Clinical Testing, Inc., 212 Cherry Lane, New Castle, DE 19720, 302-655-5227
- MedTox Laboratories, Inc., 402 W. County Rd. D, St. Paul, MN 55112, 800-832-3244/612-636-7466
- Methodist Hospital of Indiana, Inc., Department of Pathology and Laboratory Medicine, 1701 N. Senate Blvd., Indianapolis, IN 46202, 317-929-3587
- Methodist Medical Center Toxicology Laboratory, 221 N.E. Glen Oak Ave., Peoria, IL 61636, 800-752-1835/309-671-5199
- MetPath Laboratories, 875 Greentree Rd., 4 Parkway Ctr., Pittsburgh, PA 15220-3610, 412-931-7200 (formerly: Med-Chek Laboratories, Inc., Med-Chek/Damon)
- MetroLab-Legacy Laboratory Services, 235 N. Graham St., Portland, OR 97227, 503-413-4512, 800-237-7808(x4512)
- National Psychopharmacology Laboratory, Inc., 9320 Park W. Blvd., Knoxville, TN 37923, 800-251-9492
- National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 805-322-4250
- Northwest Toxicology, Inc., 1141 E. 3900 South, Salt Lake City, UT 84124, 800-322-3361
- Oregon Medical Laboratories, P.O. Box 972, 722 East 11th Ave., Eugene, OR 97440-0972, 503-687-2134
- Pathology Associates Medical Laboratories, East 11604 Indiana, Spokane, WA 99206, 509-926-2400
- PDLA, Inc. (Princeton), 100 Corporate Court, So. Plainfield, NJ 07080, 908-769-8500/800-237-7352
- PharmChem Laboratories, Inc., 1505-A O'Brien Dr., Menlo Park, CA 94025, 415-328-6200/800-446-5177
- PharmChem Laboratories, Inc., Texas Division, 7606 Pebble Dr., Fort Worth, TX 76118, 817-595-0294 (formerly: Harris Medical Laboratory)
- Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210, 913-338-4070/800-821-3627 (formerly: Physicians Reference Laboratory Toxicology Laboratory)
- Poisonlab, Inc., 7272 Clairemont Mesa Rd., San Diego, CA 92111, 619-279-2600/800-882-7272
- Presbyterian Laboratory Services, 1851 East Third Street, Charlotte, NC 28204, 800-473-6640
- Puckett Laboratory, 4200 Mamie St., Hattiesburgh, MS 39402, 601-264-3856/800-844-8378
- Scientific Testing Laboratories, Inc., 463 Southlake Blvd., Richmond, VA 23236, 804-378-9130
- Scott & White Drug Testing Laboratory, 600 S. 25th St., Temple, TX 76504, 800-749-3788
- S.E.D. Medical Laboratories, 500 Walter NE, Suite 500, Albuquerque, NM 87102, 505-848-8800
- Sierra Nevada Laboratories, Inc., 888 Willow St., Reno, NV 89502, 800-648-5472
- SmithKline Beecham Clinical Laboratories, 7600 Tyrone Ave., Van Nuys, CA 91045, 818-376-2520
- SmithKline Beecham Clinical Laboratories, 801 East Dixie Ave., Leesburg, FL 34748, 904-787-9006 (formerly: Doctors & Physicians Laboratory)
- SmithKline Beecham Clinical Laboratories, 3175 Presidential Dr., Atlanta, GA 30340, 404-934-9205 (formerly: SmithKline Bio-Science Laboratories)
- SmithKline Beecham Clinical Laboratories, 506 E. State Pkwy., Schaumburg, IL 60173, 708-885-2010 (formerly: International Toxicology Laboratories)
- SmithKline Beecham Clinical Laboratories, 400 Egypt Rd., Norristown, PA 19403, 800-523-5447 (formerly: SmithKline Bio-Science Laboratories)
- SmithKline Beecham Clinical Laboratories, 8000 Sovereign Row, Dallas, TX 75247, 214-638-1301 (formerly: SmithKline Bio-Science Laboratories)
- SmithKline Beecham Clinical Laboratories, 1737 Airport Way South, Suite 200, Seattle, WA 98134, 206-623-8100
- South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 219-234-4176
- Southwest Laboratories, 2727 W. Baseline Rd., Suite 6, Tempe, AZ 85283, 602-438-8507
- St. Anthony Hospital (Toxicology Laboratory), P.O. Box 205, 1000 N. Lee St., Oklahoma City, OK 73102, 405-272-7052

Toxicology & Drug Monitoring Laboratory,  
University of Missouri Hospital & Clinics,  
301 Business Loop 70 West, Suite 208,  
Columbia, MO 65203, 314-882-1273

Toxicology Testing Service, Inc., 5426 N.W.  
79th Ave., Miami, FL 33166, 305-593-  
2260

TOXWORX Laboratories, Inc., 6160 Variel  
Ave., Woodland Hills, CA 91367, 818-226-  
4373 (formerly: Laboratory Specialists,  
Inc.; Abused Drug Laboratories; MedTox  
Bio-Analytical, a Division of MedTox  
Laboratories, Inc.),

UNILAB, 18408 Oxnard St., Tarzana, CA  
91356, 800-492-0800/818-343-8191  
(formerly: MetWest-BPL Toxicology  
Laboratory)

No laboratories withdrew from the  
Program during July.

**Richard Kopanda,**

*Acting Executive Officer, Substance Abuse  
and Mental Health Services Administration.*

[FR Doc. 95-19062 Filed 8-2-95; 8:45 am]

BILLING CODE 4160-20-U

**Supplement to Renovate the Alcohol  
Detention Center, Page, Arizona**

**AGENCY:** Center For Substance Abuse  
Treatment, Substance Abuse and Mental  
Health Services Administration  
(SAMHSA), HHS.

**ACTION:** Notice of intent to provide a  
supplemental award to renovate a  
facility to serve the substance abuse  
needs of the people of Page, Arizona,  
and the western portion of the Navajo  
Nation.

**SUMMARY:** The Center for Substance  
Abuse Treatment (CSAT), SAMHSA, is  
publishing this notice to provide  
information to the public of a planned  
single source supplemental award to the  
Navajo Nation Division of Health for  
renovating a facility (i.e., the Alcohol  
Detention Center of Page, Arizona, and  
the western portion of the Navajo  
Nation). The anticipated project period  
is one year and the estimated FY 1995  
award is \$200,000. An award will be  
made based on the receipt of a  
satisfactory application that is approved  
by an initial review group and the CSAT  
National Advisory Council.

**AUTHORITY/JUSTIFICATION:** This  
supplemental award will be made under  
the authority of section 510(b)(1) of the  
Public Health Service Act, as amended.  
An award is being made on a single  
source basis because the Conference  
Report to the Treasury/Postal Service  
and General Appropriations Act of  
1995, specified that \$200,000 should be  
reserved for this renovation effort.

The Catalog of Federal Domestic  
Assistance number for this program is  
93.122.

The Navajo Nation Division of Health  
is a current CSAT Rural, Remote and

Culturally Distinct program grantee that  
is currently providing substance abuse  
services to the people of Page, Arizona,  
and the rural remote population in the  
western portion of the Navajo Nation, by  
utilizing the resources and existing  
network of local private and public,  
social, health and welfare organizations  
and agencies. It has been selected for a  
supplemental award for renovations to  
its Alcohol Detention Center to further  
address the special substance abuse  
problems of these populations.

The Navajo Nation has utilized this  
facility since 1981 for drug and alcohol  
treatment activities. The facility is  
currently being used to serve  
individuals targeted by the CSAT  
program. However, the facility requires  
renovations to provide 13 adult  
residential treatment beds for men and  
women which can be licensed by the  
State of Arizona.

The Navajo Nation Division of Health  
is the local entity with a developed  
infrastructure and ongoing collaborative  
arrangements with local officials most  
able to implement this renovation  
project with a minimum of start up  
time.

The Navajo Nation is extremely rural.  
Lack of transportation and  
communication are common problems.  
Further, there is a greater need than  
availability of basic medical and health  
care services. In 1992, the Navajo Nation  
Department of Health reported that  
approximately 55,000 Navajos  
participated in various treatment and  
counseling interventions. Alcohol  
related deaths, accidents, injuries,  
illness, violence, and driving while  
intoxicated are significant problems. For  
example, five of the nine leading causes  
of mortality for Navajos are accidents,  
heart disease, homicide, suicide, and  
chronic liver disease and cirrhosis.  
Alcohol can be a major contributing  
factor to each of these problems.

Based on Indian Health Service (IHS)  
statistics, Navajo youth aged 12-18 and  
young adults aged 19-35 (especially  
male) are the high risk groups for  
substance abuse, with about one-fourth  
having abused alcohol, marijuana, and/  
or inhalants. In any given community  
on the reservation or border town,  
substance abuse is highly prevalent.  
Further, 35% of 8th grade Navajo  
students off the reservation have used  
alcohol and/or other drugs of abuse.

The Navajo Nation Department of  
Health reports a limited residential  
capacity including only 28 youth drug  
treatment beds and no adult beds. The  
number of beds are inadequate to meet  
the inpatient treatment needs of the  
Navajo Nation.

**FOR FURTHER INFORMATION CONTACT:**  
Clifton D. Mitchell, Chief Special Policy  
Projects Branch, CSAT/SAMHSA,  
Rockwall II, Suite 740, 5600 Fishers  
Lane, Rockville, Maryland 20857.  
Telephone number (301) 443-8804.

Dated: July 31, 1995.

**Richard Kopanda,**

*Acting Executive Officer, Substance Abuse  
and Mental Health Services Administration.*

[FR Doc. 95-19154 Filed 8-2-95; 8:45 am]

BILLING CODE 4162-20-P

**DEPARTMENT OF HOUSING AND  
URBAN DEVELOPMENT**

**Office of Administration**

[Docket No. FR-2473-N-05]

**Notice of Submission of Proposed  
Information Collection to OMB**

**AGENCY:** Office of Administration, HUD.  
**ACTION:** Notice.

**SUMMARY:** The proposed information  
collection requirement described below  
has been submitted to the Office of  
Management and Budget (OMB) for  
review, as required by the Paperwork  
Reduction Act. The Department is  
soliciting public comments on the  
subject proposal.

**ADDRESSES:** Interested persons are  
invited to submit comments regarding  
this proposal. Comments must be  
received within thirty (30) days from the  
date of this Notice. Comments should  
refer to the proposal by name and  
should be sent to: Joseph F. Lackey, Jr.,  
OMB Desk Officer, Office of  
Management and Budget, New  
Executive Office Building, Washington,  
DC 20503.

**FOR FURTHER INFORMATION CONTACT:** Kay  
F. Weaver, Reports Management Officer,  
Department of Housing and Urban  
Development, 451 7th St. SW.,  
Washington, DC 20410, telephone (202)  
708-0050. This is not a toll-free number.  
Copies of the proposed forms and other  
available documents submitted to OMB  
may be obtained from Ms. Weaver.

**SUPPLEMENTARY INFORMATION:** The  
Department has submitted the proposal  
for the collection of information, as  
described below, to OMB for review, as  
required by the Paperwork Reduction  
Act (44 U.S.C. Chapter 35).

The Notice lists the following  
information: (1) The title of the  
information collection proposal; (2) the  
office of the agency to collect the  
information; (3) the description of the  
need for the information and its  
proposed use; (4) the agency form  
number, if applicable; (5) what members